Freezing and drug combination for melanoma that has spread to the liver
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of treatments for melanoma that has spread to the liver after standard treatment. It uses freezing (cryoablation), a targeted drug (lenvatinib), chemotherapy (dacarbazine), and two immunotherapy drugs to try to shrink liver tumors and control the cancer. The goal is to see if this combined approach is safe and effective for patients whose cancer has not responded to prior therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your melanoma must have spread to the liver, with at least one liver tumor that can be treated with cryoablation (extreme cold). Each liver tumor must be smaller than 5 cm.
- You must be able to take care of yourself (fully active, no restrictions).
- You must have no history of autoimmune diseases (like lupus or rheumatoid arthritis).
- You must not have had certain prior cancer treatments (like lenvatinib or dacarbazine) that caused severe side effects.
- You must have adequate organ function, as shown by specific blood test results.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of treatments—freezing the lung tumors (cryoablation) plus two drugs (cardonilizumab and bevacizumab)—for people with liver cancer that has spread only to their lungs. It may be an option if your first treatment stopped working but your liver tumors are under control.
This trial tests whether combining a local treatment that freezes a tumor (cryoablation) with two immune “checkpoint” medicines (ipilimumab and nivolumab) can better control unresectable melanoma. It may help when melanoma has grown after prior immune therapy.
This trial tests whether freezing (cryoablation) liver metastases works better when combined with immunotherapy (sintilimab) and a targeted pill (lenvatinib). It’s for people whose cancer has spread to the liver and has not responded to earlier treatments.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
This trial tests whether freezing (cryoablation) combined with tislelizumab and lenvatinib can help shrink advanced liver cancer and improve outcomes after earlier treatments stopped working or caused side effects. It may be an option if your cancer can’t be removed with surgery and you’ve already tried one prior systemic (whole-body) treatment.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
Hear when a new Melanoma (Skin) Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.